Biologics FDA Inspections
Biologics Inspection Readiness and Compliance Support
Former FDA investigators help biologics manufacturers, sponsors, CMOs, and CDMOs prepare for inspections, respond to observations, and protect product quality.
Biologics inspection readiness
Biologics Support
FDA Biologics Services and Product Areas
Biologics inspections put manufacturing controls, clinical records, donor eligibility, lot release, and data integrity under close review. We help teams prepare before FDA asks.
Inspection Readiness Audits
Former FDA investigators review biologics quality systems, batch records, deviations, and facility controls before FDA arrives.
- PLI and PAI readiness
- cGMP and cGTP audits
- Facility walkthroughs
483 and Warning Letter Response
Biologics teams get help with root cause analysis, CAPA plans, evidence packages, and follow-up inspection preparation.
- Root cause review
- CAPA development
- Response drafting
Pre-License Inspection Prep
Teams preparing a BLA can test facility, validation, and quality records against the expectations FDA brings to a PLI.
- BLA inspection planning
- Validation review
- Clinical site readiness
Data Integrity and Part 11
Electronic records, audit trails, lab data, and batch documentation need controls that hold up during inspection.
- Audit trail checks
- 21 CFR Part 11 review
- Data governance support
Vaccines
Vaccine manufacturers need inspection-ready process validation, contamination controls, stability records, and lot release data.
- Aseptic operations
- Lot release records
- Stability support
Blood and Plasma Products
Blood and plasma operations need tight donor, processing, labeling, deviation, and adverse reaction controls.
- Collection controls
- AER setup
- Processing records
Cell and Gene Therapies
Cell and gene therapy sponsors need inspection plans for chain of identity, validation, aseptic work, and donor controls.
- CAR-T readiness
- Gene therapy controls
- Chain of identity review
HCT/Ps and Tissue Products
Human cell and tissue products require donor eligibility, registration, listing, and processing records that FDA can trace.
- 21 CFR Part 1271
- Donor eligibility
- Registration and listing
Why Work With Us
Biologics Inspection Support Built for FDA Review
Our consultants focus on the records and controls FDA asks for during biologics inspections, from batch documentation to sterility and data integrity evidence.
PLI and PAI Readiness
Prepare facility, validation, manufacturing, and quality records before approval-related inspections.
Learn MoreAseptic and Contamination Controls
Review environmental monitoring, sterility controls, deviations, and contamination response plans.
Learn MoreCAPA and Data Integrity
Connect observations to documented CAPA work, evidence, audit trails, and accountable owners.
Learn MoreClinical and Commercial Support
Support clinical-stage, launch-stage, and commercial biologics teams preparing for FDA review.
Learn MoreCommon Questions
Frequently Asked Questions
Biologics inspections often add donor eligibility, lot release, aseptic controls, clinical records, and product-specific manufacturing controls to the usual cGMP review.
FDA may inspect for routine surveillance, a PLI or PAI, a for-cause investigation, a major manufacturing change, or follow-up to prior observations.
Common risks include data integrity gaps, sterility failures, weak deviation investigations, lot release problems, and incomplete records under biologics rules.
Yes. Clinical-stage teams can get help with inspection readiness, quality systems, manufacturing records, and response planning before commercial launch.